samedan logo
 
 
 
spacer
home > ebr > autumn 2007 > crossing the pond
PUBLICATIONS
European Biopharmaceutical Review

Crossing the Pond

As European biotech companies play catch up with the US, Hanns-Peter Wiese and Dr Stephen J McCormack at Global Life Science Ventures explore the mutual benefits of transatlantic venture capital collaboration

The worldwide economy is undergoing a fundamental transformation, with far-reaching changes in many sectors of business affecting the lives of billions of people on all continents. The pace of technological and scientific development, particularly in the life sciences, will continue to have an ever-growing impact on the lives of individuals and society as a whole. These changes will present both opportunities and challenges for the life science industry and its players. The traditional pattern of big pharmaceutical companies on the one side and small biotechnology start-ups on the other is fading, with a group of biotechnology companies, primarily from the US, having built fully integrated businesses that are publicly listed at comparable capitalisations. Both are in need of innovative technologies and new products to fill their sales pipelines.

To fill the commercial gap, there is another category of international company that has come to exist between the established global players in healthcare. These are young biotech, medtech and healthcare service companies that have to manoeuvre their way to a unique competitive or strategic advantage. In some cases, they have been formed as a consequence of the identification of synergistic technologies that have been developed across the globe.

However, there are many different ways that such global start-ups can come into existence – it may be as simple as a cost advantage in manufacturing or a trained talent pool in a particular geography. Many of these companies have a single product or platform and seek to occupy a small niche in the market or have an opportunity to enter a large existing market. Therefore, venture capital (VC) has a major role to play in supporting these companies in their start-up, early-stage and more advanced stages of business development, extending well beyond simply providing capital.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Hanns-Peter Wiese is a Partner of Global Life Science Ventures with 18 years’ investment experience in private equity and life science venture capital. Since co-founding Global Life Science Ventures in 1996 he has been Managing Director of the Munich office. From 1993 he was a Director of Corporate Finance with HypoVereinsbank in Munich. Before that, Hanns-Peter was a Director with Euro Synergies SA in Paris and an Investment Manager with 3i Investors in Industry plc, in their Frankfurt office. He holds a Master’s degree in Business Administration from the University of Hamburg, Germany.

Dr Stephen J McCormack is a Partner of Global Life Science Ventures and has more than 18 years’ experience in the biopharmaceutical industry. He has been involved as CEO in the formation, capitalisation and operation of transatlantic start-up companies in biotechnology and medical technology. His experience ranges from fundamental research and technology development to intellectual property and commercialisation of therapeutics. He received his PhD in Biomolecular Science and Engineering from the University of California, Santa Barbara, and has completed the Advanced Management Program at Harvard University.

spacer
Hanns-Peter Wiese
spacer
spacer
spacer
Dr Stephen J McCormack
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cerba Research and ACT Genomics Announce Strategic Joint Venture — CerbACT Asia

This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
More info >>

White Papers

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Phlexglobal Ltd

Many sponsor organizations have already recognized the value of moving from paper to electronic Trial Master Files (eTMFs). But few sponsors have taken a more holistic approach to the TMF lifecycle and looked at the entire process from study start-up through archiving of the TMF in electronic format, also known as e-archiving. The recurring value of managing, tracking, maintaining and accessing electronic files should not stop at the point of archiving. All of the challenges of managing an active paper TMF carry through to a paper archive. All of the benefits of an electronic TMF also carry through to the electronic archive. As companies look to move their compliance assets to secure, long-term storage, it is important to consider ongoing compliance requirements, security, accessibility, efficiency and costs of archiving TMF content in a digital format.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement